The administration of diacetylmorphine (DAM) reduces the activation of the hypothalamic-pituitary-adrenal (HPA) axis in opioid-maintained patients. However, the epigenetic effects of DAM on addiction-related genes have not been investigated yet. In a randomized controlled study, we examined the immediate effects of intravenous DAM versus placebo on the promoter methylation of the POMC (pro- opiomelanocortin) and NR3C1 (glucocorticoid receptor 1) genes. Twenty-eight heroin-dependent patients on DAM-assisted treatment received either DAM or saline in a randomized crossover design and 17 healthy participants received saline only. EDTA blood samples were taken 25 min before and 10 min after the injection of DAM or saline. We found reciprocal regulation effects for DAM versus saline application regarding the methylation of POMC; while DAM injection significantly increased methylation, saline injection led to a significant decrease in methylation for patients as well as controls. NR3C1 data did not show significant changes in methylation. Injection of DAM blunted stress hormone levels and the POMC promoter methylation of heroin-dependent patients. These findings provide first preliminary insights into the epigenetic mechanisms underlying the emotional regulation effects of DAM-assisted treatment in severe heroin-dependent patients.

Keywords:
Opioid dependence, Heroin, Diacetylmorphine methylation, Hypothalamic-pituitary-adrenal axis, POMC, NR3C1
1.
Heberlein A, et al: The treatment of alcohol and opioid dependence in pregnant women. Curr Opin Psychiatry 2012; 25: 559–564.
2.
Schmidt A, et al: Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. Biol Psychiatry 2014; 76: 289–296.
3.
Blum J, et al: Acute effects of heroin on emotions in heroin-dependent patients. Am J Addict 2013; 22: 598–604.
4.
Nielsen DA, et al: Epigenetics of drug abuse: predisposition or response. Pharmacogenomics 2012; 13: 1149–1160.
5.
Sinclair D, et al: Glucocorticoid receptor 1B and 1C mRNA transcript alterations in schizophrenia and bipolar disorder, and their possible regulation by GR gene variants. PLoS One 2012; 7:e31720.
6.
Muschler MA, et al: DNA methylation of the POMC gene promoter is associated with craving in alcohol dependence. J Neural Transm 2010; 117: 513–519.
7.
Fragou D, et al: Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver. Toxicol Lett 2013; 218: 260–265.
8.
Kreek MJ, Hartman N: Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity. Ann NY Acad Sci 1982; 398: 151–172.
9.
Walter M, et al: Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol 2008; 18: 390–393.
10.
Gerber H, et al: The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence. Eur Addict Res 2012; 18: 116–123.
11.
Walter M, et al: Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial. J Clin Psychopharmacol 2013; 33: 193–198.
12.
Lewin J, et al: Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004; 20: 3005–3012.
13.
Oberlander TF, et al: Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008; 3: 97–106.
14.
Davies MN, et al: Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 2012; 13:R43.
15.
Unternaehrer E, et al: Dynamic changes in DNA methylation of stress-associated genes (OXTR, BDNF) after acute psychosocial stress. Transl Psychiatry 2012; 2:e150.
16.
Walter M, et al: Heroin reduces startle and cortisol response in opioid-maintained heroin-dependent patients. Addict Biol 2011; 16: 145–151.
17.
Kreek MJ: Opiates, opioids and addiction. Mol Psychiatry 1996; 1: 232–254.
18.
Kreek MJ, LaForge KS, Butelman E: Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710–726.
19.
Butelman ER, Yuferov V, Kreek MJ: kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 2012; 35: 587–596.
20.
Broadbear JH, et al: Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. J Pharmacol Exp Ther 1999; 289: 1641–1647.
21.
Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci 2000; 909: 186–216.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.